



(51) International Patent Classification:

A61N 5/10 (2006.01) A61K 31/706 (2006.01)
A61P 35/00 (2006.01) A61K 31/4406 (2006.01)
A61K 51/12 (2006.01) A61K 31/713 (2006.01)

(21) International Application Number:

PCT/IB2019/059331

(22) International Filing Date:

31 October 2019 (31.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/753,930 01 November 2018 (01.11.2018) US

(71) Applicant: **ALPHA TAU MEDICAL LTD.** [IL/IL];
School of Physics, Tel Aviv University, P.O. Box 39040,
6997801 Tel Aviv (IL).

(72) Inventors: **DOMANKEVICH, Vered**; 14 Beeri Street,
4526780 Hod Hasharon (IL). **KEISARI, Yona**; 8 Ha-
gaon Eliyahu Street, 5236477 Ramat Gan (IL). **KELSON,**
Itzhak; 94 Dizengoff Street, 6439606 Tel Aviv (IL).

(74) Agent: **KLIGLER, Daniel**; Kligler & Associates Patent
Attorneys LTD., P.O. Box 57651, 61576 Tel Aviv (IL).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INTRATUMORAL ALPHA-EMITTER RADIATION AND ACTIVATION OF CYTOPLASMATIC SENSORS FOR INTRACELLULAR PATHOGEN




FIG. 1

(57) Abstract: A method of treating a patient with a tumor, and kits (200) for such treatment. The method includes administering, to the patient, a substance (204) which activates cytoplasmatic sensors for intracellular pathogen in the tumor and treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor.

